Episode Details
Back to Episodes
First Human Trial of Gene Therapy for Type 2 Diabetes
Description
Groundbreaking News: First Human Trial of Gene Therapy for Type 2 Diabetes Begins
In a major breakthrough, the Netherlands has approved the first human trial of RJVA-001, a gene therapy developed by Fractyl Health. This experimental treatment aims to manage type 2 diabetes with a single procedure, potentially replacing daily or weekly medications. Unlike current drugs like Ozempic, RJVA-001 encourages the bodys pancreas to produce GLP-1 hormone naturally. The trial will involve adults with uncontrolled diabetes, who will stop their current GLP-1 medications before receiving RJVA-001. The study will monitor patients for up to five years to assess its effectiveness and safety. The first patient is expected to be treated in the latter half of 2026, marking a significant step towards a new era in managing type 2 diabetes.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/83835885e7679512